Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rakesh Popat, Alexa Laheij, Niels W.C.J. van de Donk, Richard L. Doty, Jim Omel, Brea Lipe, Leo Rasche, Ajai Chari, Kelly Kato, Shaozhou Ken Tian, Deeksha Vishwamitra, Jacqueline Speier, Jennifer Schultz, Kasey Bolyard, Kathleen Gray, Gloria Aguilar, Mariana Fernandez, Keqin Qi, Larysa Jessica Sanchez
Institutions: University College London Hospitals NHS Foundation Trust, Academic Center for Dentistry Amsterdam, Vrije Universiteit Amsterdam, University of Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Pennsylvania, University of Rochester Medicine, Universitätsklinikum Würzburg, University of California, San Francisco, Johnson & Johnson (United States), Johnson & Johnson (Netherlands), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410812769